Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia.

Abstract

Treatment outcome in congenital adrenal hyperplasia is often sub-optimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone. Twenty-eight children have completed 2 yr of follow-up in a subsequent long term randomized parallel study comparing these two treatment regimens. During 2 yr of therapy, compared to children receiving hydrocortisone, and fludrocortisone treatment, children receiving flutamide, testolactone, reduced hydrocortisone dose (average of 8.7 +/- 0.6 mg/m2 x day), and fludrocortisone had significantly (P < or = 0.05) higher plasma 17-hydroxyprogesterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone levels. Despite elevated androgen levels, children receiving the new treatment regimen had normal linear growth rate (at 2 yr, 0.1 +/- 0.5 SD units), and bone maturation (at 2 yr, 0.7 +/- 0.3 yr bone age/yr chronological age). No significant adverse effects were observed after 2 yr. We conclude that the regimen of flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone provides effective control of congenital adrenal hyperplasia with reduced risk of glucocorticoid excess. A long term study of this new regimen is ongoing.

• Authors: D P Merke, M F Keil, J V Jones, J Fields, S Hill, G B Cutler Jr
• Journal: The Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 85 Issue 3 Pg. 1114-20 (Mar 2000) ISSN: 0021-972X [Print] United States
• PMID: 10720048 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Androgen Antagonists
• Androgens
• Anti-Inflammatory Agents
• Antineoplastic Agents, Hormonal
• Hormones
• Testolactone
• Flutamide
• Hydrocortisone

Topics

• Adrenal Hyperplasia, Congenital (complications, drug therapy, pathology)
• Androgen Antagonists (administration & dosage, adverse effects, therapeutic use)
• Androgens (blood)
• Anti-Inflammatory Agents (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Agents, Hormonal (administration & dosage, adverse effects, therapeutic use)
• Bone Development (drug effects, physiology)
• Child
• Child, Preschool
• Female
• Flutamide (administration & dosage, adverse effects, therapeutic use)
• Follow-Up Studies
• Growth (physiology)
• Hormones (blood)
• Humans
• Hydrocortisone (administration & dosage, adverse effects, therapeutic use)
• Male
• Testolactone (administration & dosage, adverse effects, therapeutic use)
• Weight Gain (drug effects)